9th Aug 2016 06:39
LONDON (Alliance News) - Drugmaker AstraZeneca PLC on Tuesday said its selumetinib cancer treatment failed to meet its primary endpoint in phase 3 trials.
The FTSE 100 company said the phase 3 trial of the drug in combination with docetaxel chemotherapy as a second-line treatment for patients wiht non-small cell lung cancer failed to meet its primary goal of progression-free survival.
The trials also showed selumetinib did not have a significant effect on overall survival rates.
"A randomised Phase II trial showed promising activity of selumetinib in combination with docetaxel in patients with KRAS mutation-positive lung cancer. It is disappointing for patients that these results have not been confirmed in Phase III," said Sean Bohen, executive vice-president of global medicines development and chief medical officer at AstraZeneca.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca